ClinicalTrials.gg
RecruitingNCT06998550Updated Nov 18, 2026

Patient Experiences and the Role of Team Structures in Pulmonary Rehabilitation in Türkiye

An observational study in Pulmonary Disease and Pulmonary Rehabilitation, sponsored by Saglik Bilimleri Universitesi. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Saglik Bilimleri Universitesi · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Nov 18, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
384
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Lung Diseases with a site in Turkey — 12 open to participants now, 15 under way, 7 of them phase 3. Lung Diseases · Turkey.

Planned enrollment
3rd of 12
384 · median 121
Started
2025
with 5 others
Observational
12 of 49
5 open now
Primary completion
2027-06
later than 8 of 14 live
Registered
45th of 49
by date
Lead sponsor
3 of 49
Saglik Bilimleri Universitesi

Among the 49 studies in Lung Diseases with a site in Turkey, this one is the 3rd largest by planned enrollment of the 12 observational ones that give a count, is one of 6 that started in 2025, is one of 12 observational ones, reaches primary completion later than 8 of the 14 other live ones, and was the 45th registered.

Lung Diseases

1,159 studies on the registry are indexed under Lung Diseases; 181 are open to participants now.

Browse Lung Diseases studies →

Open to participants now

12 of the 49 studies in Lung Diseases with a site in Turkey are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 138 Lung Diseases studies recruiting now, 75 (54%) set no upper age limit and 28 (20%) stop at 75 or younger; 15 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Lung Diseases with a site in Turkey, or all of them as a file.
02

Study summary

The PRETTY Study aims to evaluate patient satisfaction with pulmonary rehabilitation (PR) services across Türkiye and to investigate how satisfaction levels are related to the organizational structures and team compositions of the PR programs. This national, multicenter, cross-sectional observational study will also identify structural and organizational factors that may enhance patient-centered care and promote the standardization of PR services.

03

Conditions studied

  • Pulmonary Disease
  • Pulmonary Rehabilitation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Group/Cohort 1 (Label): Patient Group Description: Adults with respiratory disease who have completed a PR program and will complete the Patient Satisfaction Questionnaire.

Group/Cohort 2 (Label): Program Coordinator Group Description: Healthcare professionals responsible for PR program coordination who will complete the Institutional Survey Form about organizational and team structures.

Eligibility criteria

Patient Inclusion Criteria:

  • Age ≥18 years
  • Diagnosed with a respiratory condition (e.g., , interstitial lung disease, asthma, bronchiectasis, etc.)
  • Completed a structured PR program (minimum duration and frequency as defined by national guidelines or center-specific protocols)
  • Willing and able to complete the online Patient Satisfaction Questionnaire
  • Able to provide

Patient Exclusion Criteria:

  • Ongoing participation in a PR program (only completed cases will be included)
  • Inability to complete the questionnaire due to cognitive or language barriers without a caregiver

Coordinator Inclusion Criteria:

  • Officially designated as the PR program coordinator or responsible team member
  • Affiliated with a healthcare institution (public, university-affiliated, or private) in Türkiye that provides PR services
  • Willing to complete the Institutional Survey Form regarding team structure, service delivery, and organizational characteristics
  • Authorized by the institution to provide structural data related to the PR unit

Coordinator Exclusion Criteria:

  • PR services provided on an informal or ad-hoc basis without a designated team or structure
  • Institutions not offering a structured PR program
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
384 participants (estimated)
Target follow-up
5 Days
Patient registry
Yes

Groups and cohorts

  • PatiePatient Group: Individuals Who Completed a Pulmonary Rehabilitation Programnts

    Adult patients with a respiratory disease who have completed a pulmonary rehabilitation (PR) program, regardless of the setting (inpatient, outpatient, or home-based).

    Other: Patient Satisfaction Questionnaire

  • Institutional Representative Group: Pulmonary Rehabilitation Program Coordinators

    Healthcare professionals (e.g., physiotherapists, pulmonologists, or allied health staff) who are designated as coordinators or key team members responsible for organizing and managing the pulmonary rehabilitation program in their institution.

    Other: Institutional Survey on PR Program Structure and Team Composition

Interventions

  • OtherPatient Satisfaction Questionnaire

    An online survey designed to assess patient experiences and satisfaction levels with pulmonary rehabilitation (PR) programs. The questionnaire covers aspects such as accessibility, communication, program structure, perceived outcomes, and overall satisfaction. It is administered via Google Forms and completed voluntarily by patients who have completed a PR program.

  • OtherInstitutional Survey on PR Program Structure and Team Composition

    A structured online questionnaire completed by the designated PR program coordinator or team member. It includes questions on organizational features of the PR program, such as team composition, session frequency, assessment tools, referral and admission

06

What researchers measure

Primary outcomes

  1. Patient Satisfaction Questionnaire

    An online survey designed to assess patient experiences and satisfaction levels with pulmonary rehabilitation (PR) programs. The questionnaire covers aspects such as accessibility, communication, program structure, perceived outcomes, and overall satisfaction. It is administered via Google Forms and completed voluntarily by patients who have completed a PR program.

    Time frame: Within 4 weeks after completion of the pulmonary rehabilitation program

  2. Institutional Survey on PR Program Structure and Team Composition

    A structured online questionnaire completed by the designated PR program coordinator or team member. It includes questions on organizational features of the PR program, such as team composition, session frequency, assessment tools, referral and admission criteria, and program setting (inpatient, outpatient, or home-based). This survey aims to document the structural diversity of PR services across different healthcare institutions.

    Time frame: Within 4 weeks after completion of the pulmonary rehabilitation program

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.

Of 131 non-industry observational studies under Lung Diseases, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 95. This study's planned 22 months is below that.

Counting every sponsor, half of 153 studies reached it within 36 months; a quarter within 15 and three quarters within 84.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Jun 2026 → Jun 2027 and completion Jun 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
May 31, 2025
StartActual
Jul 29, 2025
Primary completionEst.
Jun 1, 2027was Jun 2026
CompletionEst.
Jun 1, 2027was Jun 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 1, 2026→Jun 1, 2027
Nov 18, 2026
Study completion
Jun 1, 2026→Jun 1, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion Jun 1, 2026→Jun 1, 2027
    Study completion Jun 1, 2026→Jun 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06998550
Responsible party
ESRA PEHLIVAN (PhD, Saglik Bilimleri Universitesi) — Principal investigator
First posted
May 31, 2025
Start date
Jul 29, 2025
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Esra Pehlivan, Assoc Professor
Contact
esra.pehlivan@sbu.edu.tr
Fulya Senem Karaahmetoğlu, PT
Contact
fulyakaraahmet@gmail.com
+902167778777

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion